Clover Biopharmaceuticals, Ltd.

SHSC:2197 Stock Report

Market Cap: HK$1.3b

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Clover Biopharmaceuticals Past Earnings Performance

Past criteria checks 0/6

Clover Biopharmaceuticals's earnings have been declining at an average annual rate of -16.2%, while the Biotechs industry saw earnings growing at 12.7% annually.

Key information

-16.2%

Earnings growth rate

-13.6%

EPS growth rate

Biotechs Industry Growth11.0%
Revenue growth raten/a
Return on equity-2,329.7%
Net Margin-258,830.4%
Last Earnings Update30 Jun 2023

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Clover Biopharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SHSC:2197 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 230-665317996
31 Mar 230-1,5593641,230
31 Dec 220-2,4524101,465
30 Sep 220-4,1454281,757
30 Jun 220-5,8384462,048
31 Mar 220-5,9273961,937
31 Dec 210-6,0163461,826
31 Dec 200-91376228

Quality Earnings: 2197 is currently unprofitable.

Growing Profit Margin: 2197 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 2197 is unprofitable, and losses have increased over the past 5 years at a rate of 16.2% per year.

Accelerating Growth: Unable to compare 2197's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 2197 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.6%).


Return on Equity

High ROE: 2197 has a negative Return on Equity (-2329.68%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies